Pharmaceutical

SmithRx will be First PBM to Offer YUSIMRY, a Humira Biosimilar, for One-Tenth the List Price of Humira

Teaming up with Mark Cuban Cost Plus Drug Company, SmithRx will start offering members access beginning in July 2023SAN FRANCISCO,…

10 months ago

CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare Conference

ZUG, Switzerland and CAMBRIDGE, Mass., June 13, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on…

10 months ago

GRI Bio (NASDAQ: GRI) Announces Corporate Rebranding and Launch of New Website

Company reiterates commitment to providing much-needed treatment options for inflammatory, fibrotic and autoimmune diseases LA JOLLA, CA, June 13, 2023…

10 months ago

SELLAS to Participate in Maxim Group Healthcare Virtual Conference

NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a…

10 months ago

Longeveron Welcomes Three New Prominent Board Members

Seasoned Biotechnology and Corporate Management Experts, Khoso Baluch, Jeffrey Pfeffer, and Wa’el Hashad, Elected to Board at Annual Meeting of…

10 months ago

Panbela Announces Sponsored Research Agreement to Evaluate Polyamine Metabolic Inhibitor Therapy in Combination with CAR-T Cell Therapy

MINNEAPOLIS, June 13, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc . (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for…

10 months ago

ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic Target

White paper summarizes the research of leading inflammasome experts, Drs. Helen Bramlett, Juan Pablo de Rivero Vaccari, W. Dalton Dietrich,…

10 months ago

X4 Pharmaceuticals Expected to Join Russell 3000® Index

BOSTON, June 13, 2023 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a leader in the discovery and development of novel…

10 months ago